Drug Facts
Composition & Profile
Identifiers & Packaging
16 HOW SUPPLIED/STORAGE AND HANDLING BONDLIDO (lidocaine topical system) 10% is a rectangular topical system with blue printing on one side and release liner on other. It is available as the following: Carton of 28 topical systems, packaged into individual child-resistant pouches. NDC 83708-111-28 Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light.; PRINCIPAL DISPLAY PANEL - 28 Patch Pouch Carton NDC: 83708-1111-28 Rx Only BONDLIDO ® lidocaine topical system 10% For topical use only 28 topical systems 1 Pouch containing 1 Topical System Each MEDRx ® PRINCIPAL DISPLAY PANEL - 28 Patch Pouch Carton
- 16 HOW SUPPLIED/STORAGE AND HANDLING BONDLIDO (lidocaine topical system) 10% is a rectangular topical system with blue printing on one side and release liner on other. It is available as the following: Carton of 28 topical systems, packaged into individual child-resistant pouches. NDC 83708-111-28 Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light.
- PRINCIPAL DISPLAY PANEL - 28 Patch Pouch Carton NDC: 83708-1111-28 Rx Only BONDLIDO ® lidocaine topical system 10% For topical use only 28 topical systems 1 Pouch containing 1 Topical System Each MEDRx ® PRINCIPAL DISPLAY PANEL - 28 Patch Pouch Carton
Overview
BONDLIDO (lidocaine topical system) 10% is a drug-in-adhesive topical delivery system containing 200 mg lidocaine with a non-woven polyethylene terephthalate (PET) backing membrane and a PET film release liner. Lidocaine, an amide local anesthetic, is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl) (C 14 H 22 N 2 O), has a molecular weight of 234.34 g/mol, an octanol:water partition ratio of 43 at pH 7.4, is very soluble in methanol and in ethanol, is soluble in acetic acid and in diethyl ether, is practically in-soluble in water, dissolves in dilute hydrochloric acid, and has the following structure: Each BONDLIDO topical system is 10 cm × 14 cm × 0.066 cm and contains the following inactive ingredients: blue ink, hydrocarbon, lactic acid, mono- and di-glycerides, non-woven PET backing membrane, PET film, polyoxyl 40 hydrogenated castor oil, propylene carbonate, styrene/isoprene/styrene block copolymer, tartaric acid, and terpene resin. Chemical Structure
Indications & Usage
BONDLIDO (lidocaine topical system 10%) is indicated in adults for relief of pain associated with post-herpetic neuralgia (PHN). BONDLIDO contains lidocaine, an amide local anesthetic, and is indicated in adults for relief of pain associated with post-herpetic neuralgia (PHN) ( 1 ).
Dosage & Administration
Due to differences in bioavailability, the efficacy of a lidocaine topical system does not necessarily correlate with dosage strength. Refer to the dosing instructions for the specific product being used ( 2 ). Apply BONDLIDO to intact skin to cover the most painful area. Apply the prescribed number of topical systems (maximum of two) only once for up to 12 hours in a 24-hour period (2) . Apply firm pressure for 20 seconds to ensure adequate adherence. 2.1 Important Dosage and Administration Information Due to differences in bioavailability, the efficacy of a lidocaine topical system does not necessarily correlate with dosage strength (i.e., concentration). Comparing different products on a nominal percentage-for-percentage basis may be misleading and the appropriate strength for a given indication may vary by product. Refer to the dosing instructions for the specific product being used. [see Clinical Pharmacology (12.3) ] . When BONDLIDO is used concomitantly with other products containing local anesthetic agents, the total amount of drug absorbed from all formulations must be considered. 2.2 Application Instructions Clearly instruct and advise patients: to apply BONDLIDO to intact skin to cover the most painful area. Apply the prescribed number of topical systems (maximum of 2), only once for up to 12 hours within a 24-hour period. Safety has not been established for application of more than 2 BONDLIDO topical systems per day. to apply firm pressure for 20 seconds to ensure an adequate adherence. that clothing may be worn over the area of application. to remove BONDLIDO if irritation or a burning sensation occurs during application. Advise patients not to reapply until the irritation subsides. to wash hands immediately after handling BONDLIDO and to avoid contact with eyes [see Warnings and Precautions (5.5) , Patient Counseling Information (17) ]. to not store BONDLIDO outside of the sealed pouch. to apply immediately after removal from the protective pouch. to fold used BONDLIDO so that the adhesive side sticks to itself. to safely discard used BONDLIDO where children and pets cannot get to them. to never apply external heat sources, such as heating pads or electric blankets, directly to BONDLIDO because plasma lidocaine levels may be increased [see Warnings and Precautions (5.2) , Patient Counseling Information (17) ]. that BONDLIDO may not stick if it gets wet and to avoid contact with water, such as bathing, swimming, or showering, while a BONDLIDO topical system is applied. If the BONDLIDO topical system comes off completely and will not stick to the skin, advise patients that they may apply a replacement BONDLIDO topical system and take the replacement BONDLIDO topical system off at the usual removal time. Advise patients not to wear BONDLIDO for more than 12 hours within a 24-hour period.
Warnings & Precautions
Accidental Exposure : A used BONDLIDO topical system contains residual lidocaine after use. It is important for patients to store and dispose of BONDLIDO out of the reach of children, pets, and others (5.1). Excessive Dosing : Applying BONDLIDO to larger surface areas or for a longer duration than recommended could result in increased absorption and high blood concentrations of lidocaine, leading to serious adverse effects ( 5.2 ). Non-Intact Skin : May result in higher blood concentrations of lidocaine from increased absorption ( 5.2 ). External Heat Sources : External heat sources may increase drug exposure, leading to overexposure of lidocaine ( 5.2 ). Methemoglobinemia : Cases of methemoglobinemia have been reported in association with local anesthetic use ( 5.3 ). Application Site Reactions : Severe skin irritation may occur with BONDLIDO if applied for a longer period than instructed ( 5.4 ). Hypersensitivity Reactions : Patients with an allergy to PABA derivatives may have cross-sensitivity to BONDLIDO( 5.5 ). Eye Exposure : If eye contact occurs, immediately wash out the eye with water or saline and protect the eye using, for example, eyeglasses/eye wear, until sensation returns ( 5.6 ). 5.1 Accidental Exposure A used BONDLIDO topical system contains residual lidocaine after use. The potential exists for a small child or a pet to suffer serious adverse effects from chewing or ingesting new or used BONDLIDO. It is important for patients to store and dispose of BONDLIDO properly, and keep out of the reach of children, pets, and others [see Dosage and Administration (2) ] . 5.2 Excessive Dosing Lidocaine toxicity could be expected at lidocaine blood concentrations above 5 µg/mL. The blood concentration of lidocaine is determined by the rate of systemic absorption and elimination. Longer duration of application, application of more than the recommended number of BONDLIDO, smaller patients, or impaired elimination may all contribute to increasing the blood concentration of lidocaine. If lidocaine overdose is suspected, check drug blood concentration. Management of overdose includes close monitoring, supportive care, and symptomatic treatment [see Overdosage (10) ]. Improper Application and Duration of Use : Application of more than the recommended number of BONDLIDO or applying BONDLIDO for longer than the recommended wearing time (12 hours of every 24 hours) could result in increased absorption and high blood concentrations of lidocaine, leading to adverse effects. Advise patients on proper application and duration [see Patient Counseling Information (17) ] . Hepatic Disease : Impaired elimination may contribute to increasing blood concentrations of lidocaine. Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine because of their inability to metabolize lidocaine normally. Non-Intact Skin : Application to broken or inflamed skin, although not tested, may result in higher blood concentrations of lidocaine from increased absorption. BONDLIDO is only recommended for use on intact skin. Advise patients not to apply BONDLIDO to non-intact skin [see Patient Counseling Information (17) ] . External Heat Sources : External heat sources may increase drug exposure, leading to overexposure to lidocaine. Advise patients not to apply external heat sources to BONDLIDO during administration [see Patient Counseling Information (17) ]. 5.3 Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue BONDLIDO and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. 5.4 Application Site Reactions During or immediately after treatment with BONDLIDO, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. If application site reactions occur while the topical system is being worn, advise the patient to remove BONDLIDO and not to reapply until skin reactions subside. 5.5 Hypersensitivity Reactions Patients allergic to para-aminobenzoic acid (PABA) derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross-sensitivity to lidocaine. However, be aware of the potential for cross-sensitivity in patients allergic to PABA derivatives, especially if the etiologic agent is uncertain. Manage hypersensitivity reactions by conventional means. The detection of sensitivity by skin testing is of doubtful value. 5.6 Eye Exposure The contact of BONDLIDO with eyes, although not studied, should be avoided based on findings of severe eye irritation with the application of similar products in animals. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye using, for example, eye glasses/eye wear, until sensation returns.
Contraindications
BONDLIDO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product. BONDLIDO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product ( 4 ).
Adverse Reactions
The following serious adverse reactions are described elsewhere in the labeling: Accidental Exposure [see Warnings and Precautions (5.1) ] Excessive Dosing/Overexposure to Lidocaine [see Warnings and Precautions (5.2) ] Methemoglobinemia [see Warnings and Precautions (5.3) ] Application Site Reactions [see Warnings and Precautions (5.4) ] Hypersensitivity Reactions [see Warnings and Precautions (5.5) ] Eye Irritation [see Warnings and Precautions (5.6) ] The following adverse reactions associated with the use of lidocaine were identified in clinical trials or postmarketing reports for lidocaine. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and subcutaneous tissues : blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erosions, erythema, exfoliation, flushing, irritation, papules, petechia, pruritus, vesicles, and abnormal sensation. Immune system : angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria. Central Nervous System : lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, somnolence, respiratory depression and arrest. Cardiovascular : bradycardia, hypotension, and cardiovascular collapse leading to arrest. Other : asthenia, disorientation, headache, hyperesthesia, hypoesthesia, metallic taste, nausea, pain exacerbated, paresthesia, taste alteration, and vomiting. Common adverse reactions are application site reactions such as irritation, erythema, and pruritus ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact MEDRx USA, Inc. at TELEPHONE or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interactions
Antiarrhythmic Drugs: When BONDLIDO is used in patients receiving Class I antiarrhythmic drugs (such as tocainide or mexiletine), the toxic effects are additive and potentially synergistic. Consider risk/benefit during concomitant use ( 7.1 ). Local Anesthetics: When BONDLIDO is used concomitantly with other products containing local anesthetic agents, the effects are additive. The amount absorbed from all formulations must be considered for safe use ( 7.2 ). 7.1 Antiarrhythmic Drugs When BONDLIDO is used in patients receiving Class I antiarrhythmic drugs (such as tocainide or mexiletine), the toxic effects are additive and potentially synergistic. Consider risk/benefit during concomitant use. 7.2 Local Anesthetics When BONDLIDO is used concomitantly with other products containing local anesthetic agents, the effects are additive. The amount absorbed from all formulations must be considered for safe use. 7.3 Drugs That May Cause Methemoglobinemia When Used with BONDLIDO Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia : Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine
Storage & Handling
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.